Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 10287–10301 | Cite as

The interaction of hepatoma-derived growth factor and β-catenin promotes tumorigenesis of synovial sarcoma

  • Jianming Tang
  • Huijuan Shi
  • Hui Li
  • Tiantian Zhen
  • Yu Dong
  • Fenfen Zhang
  • Yang Yang
  • Anjia Han
Original Article
  • 222 Downloads

Abstract

To clarify the clinicopathological and biological role of hepatoma-derived growth factor (HDGF) and β-catenin in synovial sarcoma. Our results showed that histological type and HDGF/β-catenin expression were the two important independent prognostic factors for overall survival in synovial sarcoma patients. HDGF knockdown dramatically inhibited cellular proliferation, colony formation, and migration but induced G1 phase arrest and apoptosis in SW982 cells. Recombinant HDGF enhanced synovial sarcoma cell growth and partially retrieved the cell growth suppression in SW982 cells upon HDGF knockdown. HDGF knockdown dramatically suppressed β-catenin and its downstream gene expression in SW982 cells. Intriguingly, β-catenin knockdown dramatically suppressed HDGF expression in SW982 cells. A direct interaction of HDGF and β-catenin was found in SW982 cells. Three HDGF-binding elements in β-catenin promoter were found and specific for transcriptional activation of β-catenin in SW982 cells. In conclusion, our findings first indicate that the interaction of HDGF and β-catenin may play a crucial role in tumorigenesis of synovial sarcoma.

Keywords

Hepatoma-derived growth factor β-Catenin Synovial sarcoma Tumorigenesis 

Notes

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Grant Nos. 81272636, 81472251, and 81201582).

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Am Cancer Soc. 2009;115:3537–47.Google Scholar
  2. 2.
    Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta. 1989;183:273–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, et al. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci. 2008;99:2120–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, et al. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol. 2007;14:2141–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, et al. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol. 2006;13:159–67.CrossRefPubMedGoogle Scholar
  6. 6.
    Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep. 2005;13:1075–80.PubMedGoogle Scholar
  7. 7.
    Yang Y, Li H, Zhang F, Shi H, Zhen T, Dai S, et al. Clinical and biological significance of hepatoma-derived growth factor in Ewing’s sarcoma. J Pathol. 2013;231:323–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Wong NA, Pignatelli M. Beta-catenin—a linchpin in colorectal carcinogenesis? Am J Pathol. 2002;160:389–401.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T, Hirohashi S. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol. 2001;32:257–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Saito T, Oda Y, Sakamoto A, Tamiya S, Kinukawa N, Hayashi K, et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol. 2000;192:342–50.CrossRefPubMedGoogle Scholar
  11. 11.
    Barham W, Frump AL, Sherrill TP, Garcia CB, Saito-Diaz K, VanSaun MN, et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discov. 2013;3:1286–301.CrossRefPubMedGoogle Scholar
  12. 12.
    Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, et al. SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene. 2014;33:5006–16.CrossRefPubMedGoogle Scholar
  13. 13.
    Yang J, Everett AD. Hepatoma-derived growth factor binds DNA through the N-terminal PWWP domain. BMC Mol Biol. 2007;8:101.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ten HS, Hoekstra HJ, Bastiaannet E, Suurmeijer AJ. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: no role for SSX fusion type or ezrin expression. Appl Immunohistochem Mol Morphol. 2009;17:189–95.CrossRefGoogle Scholar
  15. 15.
    Palmerini E, Benassi MS, Quattrini I, Pazzaglia L, Donati D, Benini S, et al. Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response? Orphanet J Rare Dis. 2015;10:6.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tsai CC, Huang SC, Tai MH, Chien CC, Huang CC, Hsu YC. Hepatoma-derived growth factor upregulation is correlated with prognostic factors of early-stage cervical adenocarcinoma. Int J Mol Sci. 2014;15:21492–504.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tao F, Ye MF, Sun AJ, Lv JQ, Xu GG, Jing YM, et al. Prognostic significance of nuclear hepatoma-derived growth factor expression in gallbladder cancer. World J Gastroenterol. 2014;20:9564–9.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Yang Y, Zhen T, Zhang F, Dai S, Kang L, Liang Y, et al. P53 and hepatoma-derived growth factor expression and their clinicopathological association with Ewing family tumour. J Clin Pathol. 2014;67:235–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Hsu SS, Chen CH, Liu GS, Tai MH, Wang JS, Wu JC, et al. Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J Neuro-Oncol. 2012;107:101–9.CrossRefGoogle Scholar
  20. 20.
    Chen X, Yun J, Fei F, Yi J, Tian R, Li S, et al. Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer. Pathol Res Pract. 2012;208:437–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Lin YW, Li CF, Chen HY, Yen CY, Lin LC, Huang CC, et al. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol. 2012;48:629–35.CrossRefPubMedGoogle Scholar
  22. 22.
    Pretto D, Barco R, Rivera J, Neel N, Gustavson MD, Eid JE. The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene. 2006;25:3661–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Song Y, Hu Z, Long H, Peng Y, Zhang X, Que T, et al. A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma. J Neurooncol. 2014;119:285–95.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Jianming Tang
    • 1
  • Huijuan Shi
    • 1
  • Hui Li
    • 1
  • Tiantian Zhen
    • 1
  • Yu Dong
    • 1
  • Fenfen Zhang
    • 1
  • Yang Yang
    • 1
  • Anjia Han
    • 1
  1. 1.Department of Pathologythe First Affiliated Hospital, Sun Yat-Sen UniversityGuangzhouChina

Personalised recommendations